Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Acquisitions (2021 - 2022)

Bioventus (BVS) has disclosed Acquisitions for 2 consecutive years, with $104.6 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Acquisitions rose 328.46% year-over-year to $104.6 million, compared with a TTM value of $367.7 million through Oct 2022, changed N/A, and an annual FY2021 reading of $262.9 million, changed N/A over the prior year.
  • Acquisitions was $104.6 million for Q4 2022 at Bioventus, up from -$5000.0 in the prior quarter.
  • Across five years, Acquisitions topped out at $262.9 million in Q4 2021 and bottomed at -$45.8 million in Q4 2021.